Warning Letters As Public “Leverage” Should Prompt GMP Compliance – Troy
This article was originally published in The Gray Sheet
Executive Summary
FDA Chief Counsel Daniel Troy emphasized the integral value of warning letters as public notification to a company's customers and competitors in a recent address to the University of Georgia's annual GMP conference
You may also be interested in...
Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity
HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.